Literature DB >> 21636807

Dietary phosphate modulates atherogenesis and insulin resistance in apolipoprotein E knockout mice--brief report.

Timothy Ellam1, Martin Wilkie, Janet Chamberlain, David Crossman, Richard Eastell, Sheila Francis, Timothy J A Chico.   

Abstract

OBJECTIVE: Epidemiological studies link higher serum phosphate and the phosphatonin fibroblast growth factor 23 with cardiovascular events and atheroma, and they link lower serum phosphate with insulin resistance and the metabolic syndrome. We investigated whether manipulating dietary phosphate influences atherogenesis or insulin sensitivity in mice. METHODS AND
RESULTS: Apolipoprotein E knockout mice were fed an atherogenic diet with low (0.2%), standard (0.6%), or high (1.6%) phosphate content. Serum phosphate and fibroblast growth factor 23 significantly increased with increasing dietary phosphate intake, but lipid profile and blood pressure were unaffected. After 20 weeks, mice on the higher phosphate diet had significantly more atheroma at the aortic sinus (42±1.9% versus 30±1.5% for high versus low phosphate, P<0.01). Compared with standard and high-phosphate diet groups, mice on a low-phosphate diet had more adipose tissue and a 4-fold increase in insulin resistance measured by homeostatic model assessment (43.7±9.3 versus 8.9±0.7 for low versus high phosphate, P<0.005).
CONCLUSIONS: A high-phosphate diet accelerates atherogenesis in apolipoprotein E(-/-) mice, whereas low phosphate intake induces insulin resistance. These data indicate for the first time that controlling dietary phosphate intake may influence development of both atherosclerosis and the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21636807     DOI: 10.1161/ATVBAHA.111.231001

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  9 in total

Review 1.  Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease.

Authors:  Armando Luis Negri
Journal:  Int Urol Nephrol       Date:  2013-01-08       Impact factor: 2.370

2.  Phosphate and CVD: it's all in what's on the table.

Authors:  Gary E Striker; Fabrizio Grosjean; Helen Vlassara
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-09       Impact factor: 8.311

3.  Cross-sectional analysis of the health profile and dietary intake of a sample of Canadian adults diagnosed with non-alcoholic fatty liver disease.

Authors:  Michelle L Aktary; Lindsay K Eller; Alissa C Nicolucci; Raylene A Reimer
Journal:  Food Nutr Res       Date:  2020-09-18       Impact factor: 3.894

Review 4.  Regulation of serum phosphate.

Authors:  Eleanor Lederer
Journal:  J Physiol       Date:  2014-06-27       Impact factor: 5.182

Review 5.  Strategies for Phosphate Control in Patients With CKD.

Authors:  Fellype Carvalho Barreto; Daniela Veit Barreto; Ziad A Massy; Tilman B Drüeke
Journal:  Kidney Int Rep       Date:  2019-06-20

6.  The relation between serum phosphorus levels and long-term mortality in Chinese patients with ST-segment elevation myocardial infarction.

Authors:  Guo-Hua Zhu; Xi-Peng Sun; Zhi Liu; Zhen-Xing Fan; Yan-Ling Wang; Jing Tan; Jing Li; Qi Hua
Journal:  J Geriatr Cardiol       Date:  2019-10       Impact factor: 3.327

7.  Phosphate Burden and Organ Dysfunction.

Authors:  Nikolay Mironov; Azeddine Atfi; Mohammed S Razzaque
Journal:  Front Aging       Date:  2022-07-14

8.  Vitamin D deficiency and exogenous vitamin D excess similarly increase diffuse atherosclerotic calcification in apolipoprotein E knockout mice.

Authors:  Timothy Ellam; Abdul Hameed; Risat ul Haque; Munitta Muthana; Martin Wilkie; Sheila E Francis; Timothy J A Chico
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

9.  High phosphate diet suppresses lipogenesis in white adipose tissue.

Authors:  Yukiko Imi; Norie Yabiki; Maerjianghan Abuduli; Masashi Masuda; Hisami Yamanaka-Okumura; Yutaka Taketani
Journal:  J Clin Biochem Nutr       Date:  2018-07-11       Impact factor: 3.114

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.